HOT StuffAll companies ↗

Physical deep technology

NVision

NVision sells preclinical MRI hyperpolarisation equipment and is developing molecular qubits on photonic chips; the two products have different evidence and readiness. [16] [1] [23] analysis

CountryGermany

Disclosure

Your heat score

Not rated

Your personal rating, from 0 to 100.

Set your score

Saved only in this browser. Your rating is an opinion, separate from the evidence.

Materials into two different products

Schematic of company-described MRI supply and proposed computing integration.

Complete participants, relationships and sources

Parahydrogen and kits

company claim

NVision supplies parahydrogen bottles and precursor/catalyst inputs; upstream vendors are undisclosed. [17] [16]

No quantities or payments are implied.

POLARIS current product and preclinical specifications

Publication date not recorded; Accessed 2026-11-01

Open original source

POLARIS at the lab

company claim

Polarisation transfer and purification produce the imaging agent. [17]

No quantities or payments are implied.

NVision support

company claim

Company markets equipment, consumables, training and maintenance. [16]

No quantities or payments are implied.

POLARIS current product and preclinical specifications

Publication date not recorded; Accessed 2026-11-01

Open original source

MRI research laboratory

company claim

Imaging research users receive equipment, consumables and support. [19] [16]

No quantities or payments are implied.

NVision Cambridge research installation

Published 2026-03-03; Accessed 2026-11-01

Open original source

POLARIS current product and preclinical specifications

Publication date not recorded; Accessed 2026-11-01

Open original source

HyperLight photonics

company claim

Named photonic-circuit integration partner. [1]

No quantities or payments are implied.

NVision HyperLight integration announcement

Published 2026-10-28; Accessed 2026-11-01

Open original source

PIQC development

company claim

Molecular films and photonic circuits are being integrated. [1]

No quantities or payments are implied.

NVision HyperLight integration announcement

Published 2026-10-28; Accessed 2026-11-01

Open original source

Consumables offered

company claim

NVision support → Parahydrogen and kits

NVision offers precursor, catalyst and parahydrogen consumables for the POLARIS workflow. [16] [17]

What happens
NVision offers precursor, catalyst and parahydrogen consumables for the POLARIS workflow.
Why it matters
The research site needs the process inputs as well as the polarisation equipment.
What follows
The inputs are prepared for the instrument; supplier identities and quantities purchased are not depicted.

Schematic direction only; no scale or timing encoded.

POLARIS current product and preclinical specifications

Publication date not recorded; Accessed 2026-11-01

Open original source

Process inputs

company claim

Parahydrogen and kits → POLARIS at the lab

Parahydrogen and the engineered precursor enter the POLARIS polarisation process. [17]

What happens
Parahydrogen and the engineered precursor enter the POLARIS polarisation process.
Why it matters
The process transfers spin order into the tracer rather than producing an MRI image itself.
What follows
Purification prepares the imaging agent for the separate research imaging workflow.

Schematic direction only; no scale or timing encoded.

Purified tracer

company claim

POLARIS at the lab → MRI research laboratory

POLARIS prepares a hyperpolarised imaging agent for use by the MRI research laboratory. [16] [17]

What happens
POLARIS prepares a hyperpolarised imaging agent for use by the MRI research laboratory.
Why it matters
The agent provides an enhanced signal for investigating metabolism with a separate MRI system.
What follows
The laboratory performs its research imaging protocol; this arrow does not establish patient efficacy or clinical approval.

Schematic direction only; no scale or timing encoded.

POLARIS current product and preclinical specifications

Publication date not recorded; Accessed 2026-11-01

Open original source

Training and service

company claim

NVision support → MRI research laboratory

NVision offers training, maintenance and acquisition support to laboratories using POLARIS. [16]

What happens
NVision offers training, maintenance and acquisition support to laboratories using POLARIS.
Why it matters
The research site needs help operating and maintaining the platform alongside its own imaging workflow.
What follows
Research conditions and service terms need confirmation; service uptake and contract values are not specified.

Schematic direction only; no scale or timing encoded.

POLARIS current product and preclinical specifications

Publication date not recorded; Accessed 2026-11-01

Open original source

Chip integration

company claim

HyperLight photonics → PIQC development

HyperLight and NVision plan to integrate molecular-qubit films with photonic integrated circuits. [1]

What happens
HyperLight and NVision plan to integrate molecular-qubit films with photonic integrated circuits.
Why it matters
The circuits provide the photonic platform for the proposed chip-based quantum-computing approach.
What follows
The partners must demonstrate the integrated device; the announcement does not establish volume production.

No volume supply or exclusive sourcing contract established.

NVision HyperLight integration announcement

Published 2026-10-28; Accessed 2026-11-01

Open original source

Scope. Two branches do not exchange products. No upstream supplier is invented; integration partners are not treated as volume suppliers.

Diagram

Two products, two stages of evidence

POLARIS prepares an MRI tracer; PIQC proposes a network of molecular quantum nodes.

Use Enlarge drawing for detail. The tour caption explains the selected elements.

POLARIS MRI preparation and proposed PIQC chipPOLARISPreclinical product offered for orderClinical model: under developmentParahydrogenprovided in bottlesPrecursor + catalystcarbon-13 labelRF1 Hydrogenate2 Transfer spin order3 Cleave / purifyPOLARIS principleTracerPurified agent is injected for research imaging.MRI measures metabolisme.g. pyruvate to lactateSeparate MRI system and suitable carbon-13 acquisition.PIQCProposed molecular nodes on a photonic chipNode AelectronnucleusresonatorNode BelectronnucleusresonatorSwitched optical pathsPhoton detectionand heralding stationHerald informationLaser and microwave control are required; links are conditional.Established experiment: one addressed molecule at 4.5 K.The chip network above is a proposal, not a proven processor.

Step 1 of 3: Prepare an imaging agent. Static diagram.

Guided reading, not physical motion.

Step timings allow time to read. They do not represent physical speed or duration.

  1. Prepare an imaging agent

    Parahydrogen and an engineered precursor enter POLARIS. The published method uses a catalytic reaction and radiofrequency spin transfer, then removes the side arm and impurities. The purified carbon-13 tracer is measured using a separate MRI system in research workflows.

  2. Connect proposed quantum nodes

    In PIQC, a molecular electron spin supplies an optical interface and a nuclear spin is intended as memory. Resonators and switched waveguides route photons to a detection station. Successful heralding is intended to link remote nodes; local microwave control completes the proposed gate sequence.

  3. Keep the evidence separate

    The published single-molecule experiment is a cryogenic crystal study at 4.5 K, not an operating PIQC computer. POLARIS Preclinical is offered for order; its Clinical counterpart remains under development.

The upper panel follows the material path from a gas bottle and precursor vial through a polariser to a tracer syringe and MRI scanner. The lower panel shows two proposed molecular nodes above resonators, with waveguides meeting a photon-detection station and a classical herald signal. Both panels are schematic.

Sources. [16] [17] [18] [22] [23] [21]

Limitations.

  • Original explanatory drawing. No engineering dimensions, yield, timing, photon-loss tolerance, clinical efficacy or computational advantage are encoded. POLARIS internals follow the published prototype principle, not a current engineering cutaway. PIQC is a proposed system; clinical POLARIS is under development.
Evidence
  • company claim. POLARIS Preclinical is offered for research use; the Clinical model is labelled under development. The product prepares hyperpolarised agents for MRI. [16]
  • company claim. Published PHIP-SAH workflow adds parahydrogen to a precursor side arm, transfers spin order to carbon-13 with radiofrequency control, then cleaves and purifies the tracer. [21] [17]
  • company claim. PIQC proposes molecular electron-spin interfaces and nuclear memories on photonic resonators, with switched optical paths and heralding detectors linking nodes. [23] [18]
  • analysis. The single-molecule experiment uses a crystal, light and microwave control at 4.5 K. It does not demonstrate the complete proposed chip processor. [22] [23]

Diagram elements

  • polaris-title: explanatory simplification. Product identity and readiness Key Benefits model labels and product specifications [16] Limitation. Company product imagery, not clinical approval.
  • inputs: explanatory simplification. Parahydrogen bottle and precursor inputs Precise Spin Control steps 1 to 3 [17] Limitation. Chemical icons are symbolic, not molecular structures.
  • process: explanatory simplification. Hydrogenation, radiofrequency transfer and purification within equipment Original article Figure 1, PDF page 76; supplementary Experimental Procedures, PDF page 86 [21] Limitation. Published prototype operations; current internal plumbing is undisclosed. Non-cryogenic does not mean every reaction is at ambient temperature.
  • scan: explanatory simplification. Purified tracer goes to MRI research measurement Prepare, Polarize, Scan workflow and preclinical specifications [16] Limitation. MRI scanner is separate and requires suitable carbon-13 acquisition; no patient approval implied.
  • piqc-title: explanatory simplification. Proposed chip architecture title Figure 3 and Section IV, PDF page 6 [23] Limitation. Not a photograph or a delivered processor.
  • nodes: explanatory simplification. Two schematic cells each containing electron interface and nuclear memory over resonator Figure 3 and Section IV A, PDF page 6 [23] Limitation. Illustrative two-cell arrangement, not fabricated geometry or qubit count.
  • routing: explanatory simplification. Routes to photon-detection station and herald information Figure 4 and Section IV B, PDF page 7 [23] Limitation. Double-click protocol in paper; no deterministic gate or always-perfect fidelity claim.
  • boundary: explanatory simplification. Separates 4.5 K single-molecule evidence from proposed integrated system Figure 1f, PDF page 2; Single Spin Readout, PDF page 5 [22] Limitation. No full processor, yield or useful computation demonstrated by this experiment.

Interactive 3D explainer

Two systems, two uses of quantum physics

Explore the proposed PIQC optical computer, then the separate POLARIS instrument used to prepare metabolic research tracers.

The static explanation below is available without 3D or JavaScript.

Evidence boundary. PIQC views explain a preprint proposal, not a delivered chip. POLARIS follows the available preclinical exterior; process views explain published research, not its hidden plumbing. Motion is schematic.

Static explanation and all component roles
  1. Proposed chip: a stationary explanatory view, not measured motion.
  2. Cell roles: a stationary explanatory view, not measured motion.
  3. Optical route: a stationary explanatory view, not measured motion.
  4. Herald measurement: a stationary explanatory view, not measured motion.
  5. Research instrument: a stationary explanatory view, not measured motion.
  6. Process inputs: a stationary explanatory view, not measured motion.
  7. Published transfer: a stationary explanatory view, not measured motion.
  8. Published separation: a stationary explanatory view, not measured motion.
  9. Research scan: a stationary explanatory view, not measured motion.
Electron-spin interface
Light addresses the proposed molecular electron-spin interface.

Purpose. It links a stationary cell to travelling photons.

Enlarged role symbol, not an atom trajectory or fabricated processor.

analysis | inspected 2026-11-01 | Source 1 | Source 2

Nuclear-spin memory
A distinct nuclear-spin role stores the proposed register.

Purpose. Storage and optical communication perform different jobs.

Memory operations in the integrated proposal are not demonstrated by the optical interface alone.

analysis | inspected 2026-11-01 | Source 1

Optical resonator
A cavity couples each proposed molecular cell to an optical path.

Purpose. Light needs a controlled route from the cell into the circuit.

Illustrative two-cell topology from a preprint, not measured chip dimensions.

analysis | inspected 2026-11-01 | Source 1

Photonic routing
Selected routes connect two cells with the same measurement station.

Purpose. Their photons must reach a common measurement path.

Two cells are a teaching example. Paths are schematic, not a fabricated mask.

analysis | inspected 2026-11-01 | Source 1

Herald measurement
The proposed double-click protocol confirms a successful link; unsuccessful attempts must be repeated.

Purpose. A missing confirmation cannot be treated as a usable link.

Status symbols explain the protocol. No success probability or literal photon experiment is simulated.

analysis | inspected 2026-11-01 | Source 1

POLARIS Preclinical
The available preclinical cabinet automates research-tracer preparation.

Purpose. Repeatable laboratory preparation supports metabolic imaging research.

Photographed preclinical exterior. The separate clinical design is under development; hidden interiors remain opaque.

company claim | inspected 2026-11-01 | Source 1

Parahydrogen supply
Prepared hydrogen supplies spin order to the chemical workflow.

Purpose. The tracer needs an external polarisation resource.

Cylinder appearance follows company imagery. The connecting arrow is a role, not installed plumbing.

company claim | inspected 2026-11-01 | Source 1 | Source 2

Precursor and catalyst
Precursor and catalyst support hydrogenation in the published preparation.

Purpose. The chemical starting material makes the transfer route possible.

Current kit formulation is undisclosed. The published prototype includes heating.

company claim | inspected 2026-11-01 | Source 1 | Source 2

Published RF transfer
A radiofrequency sweep transfers polarisation to carbon-13 in the published prototype.

Purpose. The measured carbon nucleus needs the transferred spin order.

Shield and waveform are functional symbols, not current internal hardware or measured fields.

analysis | inspected 2026-11-01 | Source 1 | Source 2

Published purification
Cleavage and phase separation recover an aqueous tracer phase.

Purpose. The imaging material must be separated from process residues.

Published research workflow. Phase volumes, purity and recovery rate are not simulated.

analysis | inspected 2026-11-01 | Source 1 | Source 2

Research imaging output
The prepared tracer feeds a separate research scan.

Purpose. POLARIS prepares material; the scanner makes the measurement.

Scanner silhouette and readout symbol are explanatory, not a patient image or clinical authorisation.

analysis | inspected 2026-11-01 | Source 1 | Source 2

company claim; analysis geometry · NVision source. Source inspection dates are listed for each component. Publication date is recorded in the dossier source list where established. Every shape is an explanatory simplification; the scene does not establish engineering performance.

Capital, customers and market direction

Money and market

Evidence checked to . Company finances and wider-market indicators are kept separate.

Announced Series B

USD 55m

NVision announced financing anchored by Abbott, including a USD 17m EIB venture loan. [F1]

The loan is included in the headline. Total capital raised is not cash or a POLARIS-only budget.

company claim

Deployment objective

About 20 centres

The May announcement expected POLARIS deployment at about 20 centres by year end. [F1]

A target is not completed installations, paid orders or recurring consumable revenue.

company claim

Diagnostics-market signal

6.4% comparable

Abbott reported Q3 Diagnostics sales growth of 46.7%, but comparable growth of 6.4% after its comparison adjustments. [F2]

The acquisition of Exact Sciences affects reported growth. Neither measure isolates MRI or NVision demand.

verified

Cash and runway

Not disclosed

Not established. Current cash, committed facilities, monthly cash burn and a funded milestone plan have not been obtained.

A financing announcement is not the cash balance. No runway estimate is shown.

analysis

What the market signal means

Separate the installed-system business from the computing option

The financial case should track accepted POLARIS installations and recurring use separately from development spending on PIQC. Abbott illustrates why acquisitions and comparability adjustments matter when reading headline growth. [F1] [F2]

No equipment price, consumable margin, clinical reimbursement or PIQC valuation is assumed.

analysis

Questions that change the financial case

  • Which installations are paid, and what revenue is recognised on acceptance?
  • What recurring contribution follows each accepted dose after kits, gases, service and quality control?
  • How is capital allocated between POLARIS commercialisation and PIQC research milestones?
Financial overview sources and dates
  1. F1 NVision Series B and platform expansion

    Published 2026-05-13 · Accessed 2026-11-01

  2. F2 Abbott Q3 2026 earnings exhibit

    Published 2026-10-21 · Accessed 2026-11-01

The development

On 28 October 2026, NVision announced a HyperLight integration partnership and Nature published its single-molecule spin-photon interface paper; related experimental and architecture preprints were already recorded in May. [1] [2] [3] [5] verified

Claims and evidence

  • NVision sells preclinical MRI hyperpolarisation equipment and is developing molecular qubits on photonic chips; the two products have different evidence and readiness. [16] [1] [23]

    analysis

  • On 28 October 2026, NVision announced a HyperLight integration partnership and Nature published its single-molecule spin-photon interface paper; related experimental and architecture preprints were already recorded in May. [1] [2] [3] [5]

    verified

  • NVision's legal notice identifies NVision Quantum Technologies GmbH in Ulm, Germany, under register number HRB 731965. [7]

    verified

  • NVision says it will combine molecular thin films with HyperLight photonic circuits, targeting prototype chips in Q4 2026 and an on-chip demonstration by year-end. [1]

    company claim

  • The company-affiliated Nature study reports optical preparation and readout, and microwave control, of individual carbene electron spins in a host crystal at 4.5 K. [2]

    company claim

  • The Nature study reports Hahn-echo coherence of 12.2(6) microseconds, XY8 dynamical-decoupling coherence of 2.2(3) milliseconds and spin relaxation of 21(2) milliseconds at 4.5 K. [2]

    company claim

  • The Nature paper reports a photobleaching-limited lifetime of about 119 hours under its stated continuous laser and microwave conditions. [2]

    company claim

  • The Nature paper reports relative fluorescence readout contrast of at most about 95%, limited mainly by background fluorescence. [2]

    company claim

  • PIQC proposes photonic links between molecular nodes, local electron-nuclear operations and distributed error correction; its system-level performance remains conditional. [6]

    analysis

  • The opened papers do not establish an operating fault-tolerant PIQC processor, customer computational advantage or a measured manufacturing yield. [6] [2]

    analysis

  • NVision's 13 May announcement describes $55 million of financing, including a $17 million EIB venture loan, and total capital raised of $120 million. [8]

    company claim

  • EIB records a EUR 15 million financing signature dated 20 December 2023 for NVision Imaging Technologies. [13]

    verified

  • DLR lists NVision as a COMIQC contractor; the project page describes development targets rather than a delivered commercial computer. [11] [12]

    verified

  • Patent publication US20250311342A1, Systems and methods for quantum computing, is dated 2 October 2025 and names NVision Imaging Technologies as original assignee. [14]

    verified

  • SWR reported on NVision's Ulm computing programme in August 2026 and described chip integration as work still to be done. [9]

    verified

  • Revenue, profitability, valuation, computing prices, gross margins, cash balance and runway are not established by the opened records. [8] [13]

    analysis

  • Current product imagery labels POLARIS Preclinical available for order and POLARIS Clinical under development. POLARIS prepares hyperpolarised metabolic agents for MRI; PIQC is a separate computing architecture in development. [16] [18]

    company claim

Assessment

TopicReading and evidence
Product and mechanismPOLARIS Preclinical prepares hyperpolarised carbon-13 tracer for MRI research and is offered for order; the Clinical model is under development. PIQC is a separate proposed photonic quantum-computing architecture. Its cryogenic single-molecule experiment does not establish a complete processor. [2] [4] [6] [16]

analysis

Customers and buying processHealthcare and drug discovery are stated ambitions; DLR provides a concrete research-programme relationship. Computing buyers, procurement criteria, prices and signed commercial orders remain unestablished. [8] [11] [12]

analysis

Commercial proofThe DLR contractor listing supports research engagement. Company-reported POLARIS MRI installations cannot be counted as PIQC computing deliveries or revenue. Acceptance, payments and computing sales are not established. [11] [12] [8]

analysis

Pricing or economicsNot established. No computing price list, unit-cost breakdown, gross-margin record or audited segment accounts were retrieved.

unknown

Competitors and substitutesThe papers compare molecular nodes with other spin interfaces and discuss ion, atom and other quantum architectures. These are not matched system benchmarks. A buyer still needs useful application performance and total cost against alternatives, including classical computation. [2] [6]

analysis

DistributionHyperLight is an announced integration counterpart, not an established PIQC sales channel. Its homepage supports photonics context, but no separate NVision-specific partner statement was located. Supply obligations, integration responsibilities and sales arrangements remain unknown. [1] [10]

analysis

Intellectual property or defensibilityAn identifiable patent application supports an IP lead. It does not establish granted exclusivity, validity or freedom to operate. Chemical design and process knowledge may help, subject to ownership, licensing and replication checks. [14] [2]

analysis

Manufacturing or operational scalingControlled crystal measurements do not establish multi-chip yield or production cost. Measure usable-emitter density, coupling, stability and preserved coherence across chips and batches before accepting scalable-manufacture claims. [2] [6] [1]

analysis

RegulationNot established. No computing-product compliance record, export classification or healthcare-use authorisation was retrieved. Obtain a product-specific compliance plan and relevant official determinations.

unknown

Capital needsThe company reports mixed equity/debt financing. EIB's opened record dates its signature to 2023; reconcile it with the May release before describing new cash. Current disbursements, restrictions, cash burn and runway are unknown. [8] [13]

analysis

Key risksUseful photon rate, optical broadening, photobleaching, integration loss and control complexity may restrict the architecture. Readout contrast is not single-shot fidelity; dynamical-decoupling coherence is not a fault-tolerant processor benchmark. [2] [6]

analysis

Next falsifiable milestoneNVision targets prototype chips in Q4 2026 and an on-chip demonstration by year-end. The useful test is repeatable multi-chip spin/optical data, measured link fidelity and rate, and disclosed failure/yield denominators. A chip photograph would not resolve those questions. [1] [2] [6]

analysis

Team and executionThe Nature author affiliations and contributions show company and academic participation in synthesis, spectroscopy and theory, with employee/shareholder interests disclosed. This is relevant expertise, not proof of manufacturing execution. Integration accountability remains to be checked. [2]

analysis

Business modelResearch contracting and eventual hardware or compute services are plausible routes. The DLR programme and company roadmap do not establish a PIQC pricing model, recurring-revenue stream or order book. [11] [12] [8]

analysis

Evidence and chronologyThe May preprints prevent an October invention claim. Final Nature publication is confirmed; the chip collaboration remains an announcement. The architecture manuscript also gives conflicting relaxation figures, so use the experimental paper with its conditions and uncertainties. [3] [5] [6] [2] [9]

analysis

Ownership and eligibilityGerman operations and the legal identity are supported. Current private independence remains unresolved without a shareholder/control record. Missing proven revenue is not itself a reason to exclude this research case. [7] [8]

analysis

Opinion

The interesting investment question is whether chemically designed emitters retain useful quantum behaviour after practical chip integration at a tolerable total cost. Final publication improves inspectability, and the named partner makes the next test more specific.

Limits. Ownership, partner obligations, independent replication and computing economics are unresolved. Strengthen the thesis only with repeatable multi-chip results, measured entanglement fidelity/rate and a costed production route. Weaken it if integration damages coherence or collection, emitter replacement undermines operation, or useful links cannot be completed within the memory budget. Missing year-end evidence warrants reassessment, not an invented technical failure.

opinion

Commercial picture · 2026-11-01

Competition, costs and demand

Current NVision Quantum Technologies: POLARIS preclinical MRI preparation and PIQC computing development are assessed separately. Evidence accessed 1 November 2026.

Research sales and development capital

Schematic of disclosed relationships, separating investment from product use.

Complete participants, relationships and sources

NVision

company claim

NVision markets POLARIS and develops PIQC. [15]

No quantities or payments are implied.

Abbott

company claim

Named strategic investor in the May financing. [8]

No quantities or payments are implied.

NVision financing and computing expansion

Published 2026-05-13; Accessed 2026-11-01

Open original source

Cambridge research

company claim

Company-reported POLARIS installation and research collaboration. [19]

No quantities or payments are implied.

NVision Cambridge research installation

Published 2026-03-03; Accessed 2026-11-01

Open original source

DLR COMIQC

verified

Documented computing research commissioning route. [12]

No quantities or payments are implied.

DLR COMIQC commissioned research project

Publication date not recorded; Accessed 2026-11-01

Open original source

Investment

company claim

Abbott → NVision

Abbott anchors NVision's reported Series B financing as a strategic investor. [8]

What happens
Abbott anchors NVision's reported Series B financing as a strategic investor.
Why it matters
The financing supports the company's development programme, including its expansion into quantum computing.
What follows
Technical and commercial milestones remain separate; Abbott's individual investment amount is undisclosed.

Schematic direction only; no scale or timing encoded.

NVision financing and computing expansion

Published 2026-05-13; Accessed 2026-11-01

Open original source

POLARIS deployment

company claim

NVision → Cambridge research

NVision reports installing POLARIS at Cambridge as part of a research collaboration. [19]

What happens
NVision reports installing POLARIS at Cambridge as part of a research collaboration.
Why it matters
The platform supplies metabolic imaging agents for research using the laboratory's MRI capability.
What follows
Researchers develop and assess applications; the deployment does not establish a disclosed sale value or clinical approval.

No payment or commercial order value is established.

NVision Cambridge research installation

Published 2026-03-03; Accessed 2026-11-01

Open original source

Research commission

verified

DLR COMIQC → NVision

DLR commissions NVision's molecular quantum-computing development through the COMIQC project. [12]

What happens
DLR commissions NVision's molecular quantum-computing development through the COMIQC project.
Why it matters
The project combines molecular materials with the control and readout systems needed to operate quantum bits.
What follows
The hardware must be developed and tested; project objectives do not establish that the machine has been completed.

No acceptance or payment amount is inferred.

DLR COMIQC commissioned research project

Publication date not recorded; Accessed 2026-11-01

Open original source

Scope. Investment, research commissioning and product installation are distinct. No revenue flows or paid purchase by a named lab are established.

Competition and substitutes

MRI preparation and quantum computing face different alternatives.

TopicEvidence and scope
MRI benchmark

The 2023 animal study compared its PHIP prototype with Oxford Instruments HyperSense dissolution DNP. This is a named historical experimental comparator, not proof of current product availability. PET and conventional MRI answer overlapping but different imaging questions. [20]

company claim

PHIP and d-DNP measurements used particular tracers, sequences and animals. No universal clinical superiority follows.

Computing alternatives

IonQ Forte, IQM Emerald and Rigetti Cepheus are named gate-based QPUs on Amazon Braket; classical simulators are also available. They compete for experimentation budgets while PIQC targets a future integrated architecture. [24]

verified

Available service names and prices do not establish matched useful-computation performance or a relationship with NVision.

Funding and financial position

Equity, debt and historical capital are separate from available cash.

TopicEvidence and scope
May financing

NVision announced USD 55 million of financing on 13 May 2026, including a USD 17 million EIB venture loan, and said total capital raised reached USD 120 million. Abbott anchored the round. [8]

company claim

These are company-reported financing figures. Do not add the included loan again or interpret total capital as cash.

Lender record

EIB records EUR 15 million signed on 20 December 2023 and an approximate EUR 53 million project cost. [13]

verified

Different currency, date and scope from the 2026 announcement. The record does not prove a second incremental loan or disbursement balance.

Cash and revenue

Not established. Current cash, debt drawn, audited revenue, burn rate and runway were not retrieved.

Not established

Financing and installations cannot substitute for accounts.

Costs and operating economics

The only retrieved service-price benchmark concerns alternative computing access.

TopicEvidence and scope
Computing OPEX benchmark

Amazon Braket lists IonQ Forte at USD 0.30 per task plus USD 0.08 per shot, or USD 7,000 per reserved hour. These are cloud-access charges for an alternative research workflow. [24]

verified

Observed 1 November 2026; ancillary AWS resources cost extra. This is not NVision pricing, a hardware CAPEX quote or cost per useful computation.

POLARIS cost structure

POLARIS is marketed with a polariser, precursor/catalyst kits, parahydrogen cylinders and service. Recurring consumables, MRI time, staff, quality control and maintenance therefore matter to cost per accepted scan. [16] [17]

analysis

No equipment or per-dose price was retrieved; three doses per hour is a company throughput claim, not utilisation or gross margin.

Capital scope

Abbott reports Diagnostics additions to property and equipment of USD 758 million in 2024 and USD 761 million in 2025. These segment totals provide scale context only. [25]

verified

Exclude property acquired in business acquisitions. Broad diagnostics investment cannot estimate a POLARIS factory or PIQC chip cost.

Missing unit economics

Not established. NVision equipment CAPEX, manufacturing yield, consumable margin, maintenance price and PIQC operating power were not retrieved.

Not established

No payback or cost advantage can be computed responsibly.

Production and supply chain

POLARIS has a described consumable route; PIQC has a named development partner.

TopicEvidence and scope
MRI input to output

NVision says it supplies centrally prepared parahydrogen in bottles and precursor/catalyst consumables. At the user site POLARIS transfers spin order, purifies the agent and supplies it for MRI measurement. [16] [17]

company claim

Upstream chemical and cylinder manufacturers, quantities, prices and exclusive agreements are not established.

Chip development

NVision and HyperLight announced integration of molecular thin films with thin-film lithium niobate photonic circuits. Quantum Machines is quoted as contributing its control platform. [1]

company claim

Development partnerships, not evidence of volume production, accepted integrated hardware or disclosed supplier contracts.

Scientific implementation

The PHIP paper uses side-arm hydrogenation followed by radiofrequency transfer and purification. The PIQC paper proposes molecular cells, resonators, optical switching and photon-detection stations. [20] [23]

company claim

Research parts lists are not a current production bill of materials.

Drivers

Two distinct adoption cases motivate the programme.

TopicEvidence and scope
Metabolic information

Hyperpolarised carbon-13 tracers can reveal conversion of pyruvate to downstream metabolites. The 2023 study compared PHIP and d-DNP imaging in rodents. [20]

company claim

Animal signal comparability does not prove diagnostic benefit, reimbursement or patient outcomes.

Integration rationale

The PIQC proposal puts molecular quantum nodes on established photonic circuits to route optical connections between nodes. HyperLight collaboration is a concrete integration step. [23] [1]

analysis

Compatibility and manufacturability remain engineering hypotheses until yield, stability and multi-node operation are measured.

Blockers

Clinical translation and scalable computation require different missing evidence.

TopicEvidence and scope
MRI readiness

Current product imagery distinguishes POLARIS Preclinical, available for order, from POLARIS Clinical, under development. The specification discusses laboratory equipment compliance. [16]

company claim

This is not evidence of approval for routine patient diagnosis. Agent quality, specialised carbon-13 acquisition and clinical validation remain material.

Qubit to processor

Single-molecule optical readout and microwave control were demonstrated in a cryogenic crystal. Nuclear memory, remote links, chip-scale fabrication and error correction form the proposed computing system. [22] [23]

analysis

No operating fault-tolerant PIQC processor, accepted chip yield or customer computational advantage was established.

Transient signal

The PHIP method must preserve polarisation during purification, transfer and acquisition; relaxation limits the available measurement window. [20]

analysis

The published prototype timing does not measure all current product workflow delays.

Demand and appetite

Installation and research commissioning are stronger signals than a market-size forecast.

TopicEvidence and scope
Imaging installation

NVision announced installation of POLARIS at Cambridge Radiology in March 2026 for translational research. Current product material includes a TUM preclinical-use testimonial. [19] [16]

company claim

Neither source discloses purchase value, payment, utilisation, repeat orders or recurring revenue.

Computing commission

DLR lists NVision in COMIQC and describes a staged goal of at least 10 then at least 50 qubits. [12]

verified

Project goals and a contractor relationship do not show delivered qubit counts, acceptance or a mass market.

Broader demand

Not established. A verified addressable-market value, PIQC order book and conversion rate from MRI trials to paid deployment were not retrieved.

Not established

Research interest is not booked commercial demand.

Buyers, users and sellers

Research institutions are visible users; prospective applications are broader.

TopicEvidence and scope
MRI channel

NVision markets the polariser, consumables and support directly to research laboratories. Cambridge and TUM are named imaging research users. [16] [19]

company claim

No distributor contract or specific paid purchase is inferred.

Computing buyer

DLR is a documented research commissioning route. Pharma, materials researchers and computing centres are plausible eventual users of molecular simulation capabilities. [12] [8]

analysis

Only the DLR relationship is documented here; prospective user classes are not named customers.

Strategic investor

Abbott is identified by NVision as the Series B anchor and sole diagnostics strategic investor. [8]

company claim

Investment is not a procurement contract, exclusive distribution arrangement or validation of clinical efficacy.

Public-company context · 2026-11-01

Listed companies around this market

Public diagnostics industry context. A company-reported strategic investment is distinguished from a trading relationship.

A listed company's share price reflects its whole business. It does not establish demand for this startup, a supplier relationship or a private valuation.

Abbott Laboratories

Industry context · analysis

Current October 2026 SEC filing verifies the symbol. NVision names Abbott as financing anchor; its Diagnostics segment supplies a disclosed industry investment benchmark. [27] [8] [25]

Investor relationship is company-reported. No supplier or customer relationship is established. Abbott is not an MRI hyperpolariser or molecular-QPU pure play.

View Abbott Laboratories on TradingView. External price data may be delayed or unavailable; filing evidence is shown below.

Diagnostics sales

Abbott Diagnostics segment, fiscal years ended 31 December. Units: USD million.

Diagnostics sales, USD million. Exact values and citations follow in the table.9,34109,34120242024-12-31: 9,341 USD million8,93720252025-12-31: 8,937 USD million
PeriodReported valueFiling and evidence
2024-01-01 to 2024-12-319,341 USD million2026-02-20 · verified
Note 16, segment sales table, page 75 [25]
2025-01-01 to 2025-12-318,937 USD million2026-02-20 · verified
Note 16, segment sales table, page 75 [25]

Broad diagnostics operations, not NVision or MRI-only economics; additions exclude acquired property.

Diagnostics property and equipment additions

Abbott Diagnostics segment, fiscal years ended 31 December. Units: USD million.

Diagnostics property and equipment additions, USD million. Exact values and citations follow in the table.761075820242024-12-31: 758 USD million76120252025-12-31: 761 USD million
PeriodReported valueFiling and evidence
2024-01-01 to 2024-12-31758 USD million2026-02-20 · verified
Note 16, additions to property and equipment table, page 76 [25]
2025-01-01 to 2025-12-31761 USD million2026-02-20 · verified
Note 16, additions to property and equipment table, page 76 [25]

Broad diagnostics operations, not NVision or MRI-only economics; additions exclude acquired property.

Calculated comparisons

2025 Diagnostics property additions / sales: 8.52% analysis · calculated, rounded to 2 decimal places

100 × 761 ÷ 8,937. Diagnostics property and equipment additions / Diagnostics sales, period ending 2025-12-31. [25]

Same segment and annual period; ratio is broad industry context, not a startup capital-intensity estimate.

Competitive landscape · 2026-11-01

Who else solves this?

Alternatives to POLARIS for producing hyperpolarised agents for metabolic MRI research. The separate molecular-qubit programme is outside this comparison.

Comparison lens. Compare agent compatibility, preparation workflow, installed research capability and total operating cost. A cryogen-free DNP instrument still uses low-temperature polarisation; it is not the same process as non-cryogenic parahydrogen chemistry. analysis

Direct competitor · International supplier; first reported installation at UCSF, USA

Bruker dDNP polariser

Dissolution dynamic nuclear polarisation instrument for liquid NMR and preclinical MRI.

Difference
An equipment alternative to POLARIS PHIP; compare substrates and preparation throughput rather than treating all signal gains as interchangeable.
Maturity
Bruker reported its first customer installation in April 2025. This is research instrumentation, not evidence of routine clinical approval.
Economics
Purchase, service and consumable prices are not disclosed in the launch. No cost-per-dose ranking is established.
Funding / ownership
Bruker identifies itself as Nasdaq-listed BRKR; product-specific investment is not disclosed.

Manufacturer speed and performance claims are not a matched comparison with POLARIS.

analysis

Sources and dates

Bruker dDNP launch and first UCSF installation (published 2025-04-02; accessed 2026-11-01) · NVision POLARIS technology (published date not stated; accessed 2026-11-01)

Direct competitor · Installed at UCSF, USA; other sales territories not established here

Polarize SpinAligner

Cryogen-free dissolution-DNP hyperpolariser recorded in the UCSF facility inventory.

Difference
A direct research-preparation alternative. Its closed-cycle cold system differs from POLARIS chemical polarisation.
Maturity
An installed research instrument is documented by a user institution.
Economics
Avoiding replenished liquid cryogens does not remove electricity, servicing or consumable costs; comparable quotes are absent.
Funding / ownership
Ownership, recent financing and current cash were not established in the inspected institutional record.

The manufacturer website timed out. Do not infer delivery lead times or present sales capacity from an installation.

analysis

Sources and dates

UCSF installed hyperpolarisation instruments (published date not stated; accessed 2026-11-01) · NVision POLARIS technology (published date not stated; accessed 2026-11-01)

Established supplier · Documented US research installations

GE SPINlab

Multi-sample DNP system producing hyperpolarised carbon-13 solutions for research.

Difference
An established preparation and quality-control workflow that competes for laboratory capital and training budgets.
Maturity
Maryland documents preclinical and clinical research use; this is not an assertion of routine-care authorisation.
Economics
Installed hardware, sterile fluid paths and quality control matter to total cost. No current sales quotation was found.
Funding / ownership
GE-branded installed equipment; present product ownership, new-sales terms and dedicated funding were not verified.

Clinical research use is not proof of approval for every agent or indication.

analysis

Sources and dates

Maryland SPINlab facility (published date not stated; accessed 2026-11-01)

Established supplier · Documented at UCSF, USA

Oxford HyperSense installed systems

Existing dissolution-DNP laboratory hardware.

Difference
Keeping an installed system can substitute for purchasing POLARIS where its agent workflow is adequate.
Maturity
UCSF lists an installed HyperSense; new-unit availability and ongoing support are unverified.
Economics
Sunk equipment cost can favour retention, but liquid-helium needs and maintenance affect operating cost. No lifecycle comparison is established.
Funding / ownership
Legacy Oxford-branded equipment; current support arrangements and product investment are unknown.

Installed-base alternative, not a claim that a new competing product is on sale.

analysis

Sources and dates

UCSF installed hyperpolarisation instruments (published date not stated; accessed 2026-11-01)

Coverage limits. This is a bounded primary-source comparison, not an exhaustive market census or independent performance test. Catalogue availability does not establish sales volume. Unreported prices, current cash and product-level funding remain unknown.

Sources

  1. 1
    NVision: October partnership announcement

    company | Published 2026-10-28 | Accessed 2026-11-01

  2. 2
    Roggors et al.: Nature version of record

    paper | Published 2026-10-28 | Accessed 2026-11-01

  3. 3
    arXiv: experimental preprint record, submission date

    paper | Published 2026-05-11 | Accessed 2026-11-01

  4. 4
    arXiv: experimental manuscript v1

    paper | Published 2026-05-11 | Accessed 2026-11-01

  5. 5
    arXiv: PIQC preprint record, submission date

    paper | Published 2026-05-20 | Accessed 2026-11-01

  6. 6
    Aubele et al.: PIQC architecture manuscript v1

    paper | Published 2026-05-20 | Accessed 2026-11-01

  7. 7
    NVision: legal imprint

    company | Published undated | Accessed 2026-11-01

  8. 8
    NVision: May financing and computing expansion

    company | Published 2026-05-13 | Accessed 2026-11-01

  9. 9
    SWR: August reporting on the Ulm programme

    independent | Published 2026-08-16 | Accessed 2026-11-01

  10. 10
    HyperLight: photonics company homepage

    partner | Published undated | Accessed 2026-11-01

  11. 11
    DLR: NVision contractor record

    programme | Published undated | Accessed 2026-11-01

  12. 12
    DLR: COMIQC project scope

    programme | Published undated | Accessed 2026-11-01

  13. 13
    EIB: NVision financing project summary

    lender | Published 2024-03-13 | Accessed 2026-11-01

  14. 14
    US20250311342A1: published patent application

    patent | Published 2025-10-02 | Accessed 2026-11-01

  15. 15
    NVision current company site

    primary source | Published undated | Accessed 2026-11-01

  16. 16
    POLARIS current product and preclinical specifications

    primary source | Published undated | Accessed 2026-11-01

  17. 17
    POLARIS PHIP workflow

    primary source | Published undated | Accessed 2026-11-01

  18. 18
    PIQC current architecture proposal

    primary source | Published undated | Accessed 2026-11-01

  19. 19
    NVision Cambridge research installation

    primary source | Published 2026-03-03 | Accessed 2026-11-01

  20. 20
    Nagel et al., PHIP preclinical study

    primary source | Published 2023-08-16 | Accessed 2026-11-01

  21. 21
    TUM thesis authorised article and supplement reproduction

    primary source | Published undated | Accessed 2026-11-01

  22. 22
    Single-molecule spin-photon interface, arXiv v1

    primary source | Published 2026-05-11 | Accessed 2026-11-01

  23. 23
    PIQC architecture, arXiv v1

    primary source | Published 2026-05-20 | Accessed 2026-11-01

  24. 24
    Amazon Braket official pricing

    primary source | Published undated | Accessed 2026-11-01

  25. 25
    Abbott 2025 Form 10-K

    official filing | Published 2026-02-20 | Accessed 2026-11-01

  26. 26
    Abbott 10-K filing date

    official filing | Published 2026-02-20 | Accessed 2026-11-01

  27. 27
    Abbott October 2026 Form 8-K listing

    official filing | Published 2026-10-21 | Accessed 2026-11-01